

# Julen Oyarzabal

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/8110646/julen-oyarzabal-publications-by-citations.pdf>

**Version:** 2024-04-23

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

103  
papers

3,679  
citations

33  
h-index

57  
g-index

115  
ext. papers

4,290  
ext. citations

7.5  
avg, IF

5.05  
L-index

#	Paper	IF	Citations
103	A cell-based screen identifies ATR inhibitors with synthetic lethal properties for cancer-associated mutations. <i>Nature Structural and Molecular Biology</i> , <b>2011</b> , 18, 721-7	17.6	358
102	Salermide, a Sirtuin inhibitor with a strong cancer-specific proapoptotic effect. <i>Oncogene</i> , <b>2009</b> , 28, 781-91	9.1	221
101	Phosphodiesterases as therapeutic targets for Alzheimer's disease. <i>ACS Chemical Neuroscience</i> , <b>2012</b> , 3, 832-44	5.7	180
100	Information Retrieval and Text Mining Technologies for Chemistry. <i>Chemical Reviews</i> , <b>2017</b> , 117, 7673-7761	6.1	124
99	CHEMDNER: The drugs and chemical names extraction challenge. <i>Journal of Cheminformatics</i> , <b>2015</b> , 7, S1	8.6	120
98	Tadalafil crosses the blood-brain barrier and reverses cognitive dysfunction in a mouse model of AD. <i>Neuropharmacology</i> , <b>2013</b> , 64, 114-23	5.5	109
97	In vivo, in vitro and in silico methods for small molecule transfer across the BBB. <i>Journal of Pharmaceutical Sciences</i> , <b>2009</b> , 98, 4429-68	3.9	109
96	The AhpC and AhpD antioxidant defense system of Mycobacterium tuberculosis. <i>Journal of Biological Chemistry</i> , <b>2000</b> , 275, 18801-9	5.4	104
95	The CHEMDNER corpus of chemicals and drugs and its annotation principles. <i>Journal of Cheminformatics</i> , <b>2015</b> , 7, S2	8.6	98
94	Binding and Signaling Studies Disclose a Potential Allosteric Site for Cannabidiol in Cannabinoid CB Receptors. <i>Frontiers in Pharmacology</i> , <b>2017</b> , 8, 744	5.6	93
93	Zebrafish: Speeding Up the Cancer Drug Discovery Process. <i>Cancer Research</i> , <b>2018</b> , 78, 6048-6058	10.1	80
92	Discovery of first-in-class reversible dual small molecule inhibitors against G9a and DNMTs in hematological malignancies. <i>Nature Communications</i> , <b>2017</b> , 8, 15424	17.4	74
91	Inhibition of a G9a/DNMT network triggers immune-mediated bladder cancer regression. <i>Nature Medicine</i> , <b>2019</b> , 25, 1073-1081	50.5	71
90	A First-in-Class Small-Molecule that Acts as a Dual Inhibitor of HDAC and PDE5 and that Rescues Hippocampal Synaptic Impairment in Alzheimer's Disease Mice. <i>Neuropsychopharmacology</i> , <b>2017</b> , 42, 524-539	8.7	65
89	Decreased levels of guanosine 3', 5'-monophosphate (cGMP) in cerebrospinal fluid (CSF) are associated with cognitive decline and amyloid pathology in Alzheimer's disease. <i>Neuropathology and Applied Neurobiology</i> , <b>2015</b> , 41, 471-82	5.2	65
88	Chemical interrogation of FOXO3a nuclear translocation identifies potent and selective inhibitors of phosphoinositide 3-kinases. <i>Journal of Biological Chemistry</i> , <b>2009</b> , 284, 28392-28400	5.4	63
87	Design, Synthesis, and Biological Evaluation of First-in-Class Dual Acting Histone Deacetylases (HDACs) and Phosphodiesterase 5 (PDE5) Inhibitors for the Treatment of Alzheimer's Disease. <i>Journal of Medicinal Chemistry</i> , <b>2016</b> , 59, 8967-9004	8.3	59

86	Dual Targeting of Histone Methyltransferase G9a and DNA-Methyltransferase 1 for the Treatment of Experimental Hepatocellular Carcinoma. <i>Hepatology</i> , <b>2019</b> , 69, 587-603	11.2	56
85	Monoacylglycerol lipase inhibitor JZL184 is neuroprotective and alters glial cell phenotype in the chronic MPTP mouse model. <i>Neurobiology of Aging</i> , <b>2014</b> , 35, 2603-2616	5.6	55
84	A simple synthesis of 3-phosphonyl-4-aminoquinolines from $\beta$ -enaminophosphonates. <i>Tetrahedron</i> , <b>1999</b> , 55, 5947-5964	2.4	54
83	Discovery of selective ligands for telomeric RNA G-quadruplexes (TERRA) through 19F-NMR based fragment screening. <i>ACS Chemical Biology</i> , <b>2014</b> , 9, 1559-66	4.9	50
82	Pim 1 kinase inhibitor ETP-45299 suppresses cellular proliferation and synergizes with PI3K inhibition. <i>Cancer Letters</i> , <b>2011</b> , 300, 145-53	9.9	50
81	Preparation of fluoroalkyl imines, amines, enamines, ketones, alpha-amino carbonyls, and alpha-amino acids from primary enamine phosphonates. <i>Journal of Organic Chemistry</i> , <b>2004</b> , 69, 8767-74	4.2	49
80	Assessment of additive/nonadditive effects in structure-activity relationships: implications for iterative drug design. <i>Journal of Medicinal Chemistry</i> , <b>2008</b> , 51, 7552-62	8.3	48
79	GPR55: A therapeutic target for Parkinson's disease?. <i>Neuropharmacology</i> , <b>2017</b> , 125, 319-332	5.5	45
78	A one pot synthesis of polysubstituted pyridines from metallated alkylphosphonates, nitriles and $\alpha$ -unsaturated ketones. <i>Tetrahedron Letters</i> , <b>1996</b> , 37, 4577-4580	2	45
77	Concomitant histone deacetylase and phosphodiesterase 5 inhibition synergistically prevents the disruption in synaptic plasticity and it reverses cognitive impairment in a mouse model of Alzheimer's disease. <i>Clinical Epigenetics</i> , <b>2015</b> , 7, 108	7.7	39
76	Synthesis of fluoroalkylated beta-aminophosphonates and pyridines from primary beta-enaminophosphonates. <i>Journal of Organic Chemistry</i> , <b>2008</b> , 73, 4568-74	4.2	39
75	Fluoroalkyl alpha,beta-unsaturated imines. Valuable synthetic intermediates from primary fluorinated enamine phosphonates. <i>Organic Letters</i> , <b>2002</b> , 4, 769-72	6.2	39
74	Fatty acid amide hydrolase inhibition for the symptomatic relief of Parkinson's disease. <i>Brain, Behavior, and Immunity</i> , <b>2016</b> , 57, 94-105	16.6	38
73	Hit to lead evaluation of 1,2,3-triazolo[4,5-b]pyridines as PIM kinase inhibitors. <i>Bioorganic and Medicinal Chemistry Letters</i> , <b>2012</b> , 22, 1591-7	2.9	36
72	Design, synthesis, biological evaluation and in vivo testing of dual phosphodiesterase 5 (PDE5) and histone deacetylase 6 (HDAC6)-selective inhibitors for the treatment of Alzheimer's disease. <i>European Journal of Medicinal Chemistry</i> , <b>2018</b> , 150, 506-524	6.8	35
71	Inhibition of FOXP3/NFAT Interaction Enhances T Cell Function after TCR Stimulation. <i>Journal of Immunology</i> , <b>2015</b> , 195, 3180-9	5.3	34
70	Pharmacokinetic investigation of sildenafil using positron emission tomography and determination of its effect on cerebrospinal fluid cGMP levels. <i>Journal of Neurochemistry</i> , <b>2016</b> , 136, 403-15	6	31
69	Repurposing ciclopirox as a pharmacological chaperone in a model of congenital erythropoietic porphyria. <i>Science Translational Medicine</i> , <b>2018</b> , 10,	17.5	31

68	Discovery of mitogen-activated protein kinase-interacting kinase 1 inhibitors by a comprehensive fragment-oriented virtual screening approach. <i>Journal of Medicinal Chemistry</i> , <b>2010</b> , 53, 6618-28	8.3	30
67	In Silico Aptamer Docking Studies: From a Retrospective Validation to a Prospective Case Study-TIM3 Aptamers Binding. <i>Molecular Therapy - Nucleic Acids</i> , <b>2016</b> , 5, e376	10.7	28
66	Discovery of Reversible DNA Methyltransferase and Lysine Methyltransferase G9a Inhibitors with Antitumoral in Vivo Efficacy. <i>Journal of Medicinal Chemistry</i> , <b>2018</b> , 61, 6518-6545	8.3	27
65	Impact of Scaffold Exploration on Novel Dual-Acting Histone Deacetylases and Phosphodiesterase 5 Inhibitors for the Treatment of Alzheimer's Disease. <i>ACS Chemical Neuroscience</i> , <b>2017</b> , 8, 638-661	5.7	26
64	Epigenetic drugs in Alzheimer's disease. <i>Biomolecular Concepts</i> , <b>2013</b> , 4, 433-45	3.7	26
63	Novel approach for chemotype hopping based on annotated databases of chemically feasible fragments and a prospective case study: new melanin concentrating hormone antagonists. <i>Journal of Medicinal Chemistry</i> , <b>2009</b> , 52, 2076-89	8.3	26
62	LimTox: a web tool for applied text mining of adverse event and toxicity associations of compounds, drugs and genes. <i>Nucleic Acids Research</i> , <b>2017</b> , 45, W484-W489	20.1	24
61	Synthesis of 5-Phosphonyl-2(1H)-pyridones from Primary $\beta$ -Enaminophosphonate and Acetylenic Esters. <i>Heterocycles</i> , <b>1995</b> , 41, 1915	0.8	24
60	Imidazo[1,2-a]pyrazines as novel PI3K inhibitors. <i>Bioorganic and Medicinal Chemistry Letters</i> , <b>2012</b> , 22, 1874-8	2.9	23
59	A simple and efficient strategy for the preparation of 5-phosphorylated imidazol-2-ones from primary $\beta$ -enaminophosphonates. <i>Tetrahedron</i> , <b>1998</b> , 54, 2281-2288	2.4	23
58	Novel Scaffold FingerPrint (SFP): applications in scaffold hopping and scaffold-based selection of diverse compounds. <i>Journal of Chemical Information and Modeling</i> , <b>2015</b> , 55, 1-18	6.1	21
57	Epigenetic mechanisms and metabolic reprogramming in fibrogenesis: dual targeting of G9a and DNMT1 for the inhibition of liver fibrosis. <i>Gut</i> , <b>2021</b> , 70, 388-400	19.2	21
56	Taking Advantage of the Selectivity of Histone Deacetylases and Phosphodiesterase Inhibitors to Design Better Therapeutic Strategies to Treat Alzheimer's Disease. <i>Frontiers in Aging Neuroscience</i> , <b>2019</b> , 11, 149	5.3	21
55	Phosphodiesterase inhibition in cognitive decline. <i>Journal of Alzheimers Disease</i> , <b>2014</b> , 42 Suppl 4, S561-73	7.3	21
54	Identification of ETP-46321, a potent and orally bioavailable PI3K $\beta$ inhibitor. <i>Bioorganic and Medicinal Chemistry Letters</i> , <b>2012</b> , 22, 3460-6	2.9	21
53	Defining the mechanism of action of 4-phenylbutyrate to develop a small-molecule-based therapy for Alzheimer's disease. <i>Current Medicinal Chemistry</i> , <b>2011</b> , 18, 5545-53	4.3	20
52	Mechanism and structure-activity relationships of norspermidine-based peptidic inhibitors of trypanothione reductase. <i>Bioorganic and Medicinal Chemistry</i> , <b>2005</b> , 13, 4513-26	3.4	20
51	Discovery of 1,5-disubstituted pyridones: a new class of positive allosteric modulators of the metabotropic glutamate 2 receptor. <i>ACS Chemical Neuroscience</i> , <b>2010</b> , 1, 788-95	5.7	19

50	ICAM-1 peptide inhibitors of T-cell adhesion bind to the allosteric site of LFA-1. An NMR characterization. <i>Chemical Biology and Drug Design</i> , <b>2007</b> , 70, 347-53	2.9	19
49	Identification of LAG3 high affinity aptamers by HT-SELEX and Conserved Motif Accumulation (CMA). <i>PLoS ONE</i> , <b>2017</b> , 12, e0185169	3.7	19
48	Multitarget Approach for the Treatment of Alzheimer's Disease: Inhibition of Phosphodiesterase 9 (PDE9) and Histone Deacetylases (HDACs) Covering Diverse Selectivity Profiles. <i>ACS Chemical Neuroscience</i> , <b>2019</b> , 10, 4076-4101	5.7	18
47	Biologically relevant chemical space navigator: from patent and structure-activity relationship analysis to library acquisition and design. <i>Journal of Chemical Information and Modeling</i> , <b>2012</b> , 52, 3123-37	6.1	18
46	An easy strategy for the synthesis of 5-phosphorylated pyrimidin-2,4-diones from phosphine oxide and phosphonate enamines. <i>Tetrahedron</i> , <b>1999</b> , 55, 3105-3116	2.4	18
45	Discovery of in Vivo Chemical Probes for Treating Alzheimer's Disease: Dual Phosphodiesterase 5 (PDE5) and Class I Histone Deacetylase Selective Inhibitors. <i>ACS Chemical Neuroscience</i> , <b>2019</b> , 10, 1765-1782	5.7	18
44	Hsp70 protects from stroke in atrial fibrillation patients by preventing thrombosis without increased bleeding risk. <i>Cardiovascular Research</i> , <b>2016</b> , 110, 309-18	9.9	17
43	Design, synthesis, and biological evaluation of novel matrix metalloproteinase inhibitors as potent antihemorrhagic agents: from hit identification to an optimized lead. <i>Journal of Medicinal Chemistry</i> , <b>2015</b> , 58, 2465-88	8.3	17
42	Rapid identification of ETP-46992, orally bioavailable PI3K inhibitor, selective versus mTOR. <i>Bioorganic and Medicinal Chemistry Letters</i> , <b>2012</b> , 22, 5208-14	2.9	17
41	A new and efficient strategy for the preparation of 1,5,2-diazaphosphorines from primary enamino-phosphonates. <i>Tetrahedron</i> , <b>1999</b> , 55, 3091-3104	2.4	17
40	Two Affinity Sites of the Cannabinoid Subtype 2 Receptor Identified by a Novel Homogeneous Binding Assay. <i>Journal of Pharmacology and Experimental Therapeutics</i> , <b>2016</b> , 358, 580-7	4.7	17
39	Detailed Exploration around 4-Aminoquinolines Chemical Space to Navigate the Lysine Methyltransferase G9a and DNA Methyltransferase Biological Spaces. <i>Journal of Medicinal Chemistry</i> , <b>2018</b> , 61, 6546-6573	8.3	16
38	Computational medicinal chemistry in fragment-based drug discovery: what, how and when. <i>Future Medicinal Chemistry</i> , <b>2011</b> , 3, 95-134	4.1	16
37	Blockage of FOXP3 transcription factor dimerization and FOXP3/AML1 interaction inhibits T regulatory cell activity: sequence optimization of a peptide inhibitor. <i>Oncotarget</i> , <b>2017</b> , 8, 71709-71724	3.3	16
36	Targeting CB and GPR55 Endocannabinoid Receptors as a Potential Neuroprotective Approach for Parkinson's Disease. <i>Molecular Neurobiology</i> , <b>2019</b> , 56, 5900-5910	6.2	15
35	Conformational selection versus induced fit in kinases: the case of PI3K- $\gamma$ . <i>Angewandte Chemie - International Edition</i> , <b>2012</b> , 51, 642-6	16.4	15
34	CM352 Reduces Brain Damage and Improves Functional Recovery in a Rat Model of Intracerebral Hemorrhage. <i>Journal of the American Heart Association</i> , <b>2017</b> , 6,	6	14
33	Fragment-hopping-based discovery of a novel chemical series of proto-oncogene PIM-1 kinase inhibitors. <i>PLoS ONE</i> , <b>2012</b> , 7, e45964	3.7	13

32	Discovery of novel triazolo[4,3-b]pyridazin-3-yl-quinoline derivatives as PIM inhibitors. <i>European Journal of Medicinal Chemistry</i> , <b>2019</b> , 168, 87-109	6.8	12
31	Synthesis of novel 2,5-dihydro-1,5,2-diazaphosphinines from primary enamine phosphonates and from alkyl phosphonates. <i>Tetrahedron</i> , <b>2005</b> , 61, 1087-1094	2.4	12
30	A novel FTY720 analogue targets SET-PP2A interaction and inhibits growth of acute myeloid leukemia cells without inducing cardiac toxicity. <i>Cancer Letters</i> , <b>2020</b> , 468, 1-13	9.9	12
29	Towards the understanding of the activity of G9a inhibitors: an activity landscape and molecular modeling approach. <i>Journal of Computer-Aided Molecular Design</i> , <b>2020</b> , 34, 659-669	4.2	11
28	Targeting aberrant DNA methylation in mesenchymal stromal cells as a treatment for myeloma bone disease. <i>Nature Communications</i> , <b>2021</b> , 12, 421	17.4	11
27	Discovery and safety profiling of a potent preclinical candidate, (4-[4-[[[(3R)-3-(hydroxycarbamoyl)-8-azaspiro[4.5]decan-3-yl]sulfonyl]phenoxy]-N-methylbenzamide) (CM-352), for the prevention and treatment of hemorrhage. <i>Journal of Medicinal Chemistry</i> , <b>2015</b> , 58, 2641-57	8.3	10
26	An Efficient Synthesis of 3-Phosphorylated 4(1H)-Pyridones and 4-Chloropyridines from b-Enaminophosphonates. <i>Heterocycles</i> , <b>1998</b> , 47, 517	0.8	10
25	Endogenous Retroelement Activation by Epigenetic Therapy Reverses the Warburg Effect and Elicits Mitochondrial-Mediated Cancer Cell Death. <i>Cancer Discovery</i> , <b>2021</b> , 11, 1268-1285	24.4	10
24	Using novel descriptor accounting for ligand-receptor interactions to define and visually explore biologically relevant chemical space. <i>Journal of Chemical Information and Modeling</i> , <b>2012</b> , 52, 1086-102	6.1	9
23	Optimizing the performance of in silico ADMET general models according to local requirements: MARS approach. solubility estimations as case study. <i>Journal of Chemical Information and Modeling</i> , <b>2009</b> , 49, 2837-50	6.1	9
22	The Markyt visualisation, prediction and benchmark platform for chemical and gene entity recognition at BioCreative/CHEMDNER challenge. <i>Database: the Journal of Biological Databases and Curation</i> , <b>2016</b> , 2016,	5	8
21	An integrated one-step system to extract, analyze and annotate all relevant information from image-based cell screening of chemical libraries. <i>Molecular BioSystems</i> , <b>2010</b> , 6, 711-20		8
20	Reversible dual inhibitor against G9a and DNMT1 improves human iPSC derivation enhancing MET and facilitating transcription factor engagement to the genome. <i>PLoS ONE</i> , <b>2017</b> , 12, e0190275	3.7	8
19	Development and Validation of Molecular Overlays Derived from Three-Dimensional Hydrophobic Similarity with PharmScreen. <i>Journal of Chemical Information and Modeling</i> , <b>2018</b> , 58, 1596-1609	6.1	7
18	2-Oxaadamant-1-yl Ureas as Soluble Epoxide Hydrolase Inhibitors: Evaluation in a Murine Model of Acute Pancreatitis. <i>Journal of Medicinal Chemistry</i> , <b>2020</b> , 63, 9237-9257	8.3	7
17	Inducing heat shock protein 70 expression provides a robust antithrombotic effect with minimal bleeding risk. <i>Thrombosis and Haemostasis</i> , <b>2017</b> , 117, 1722-1729	7	6
16	Targeting the anion exchanger 2 with specific peptides as a new therapeutic approach in B lymphoid neoplasms. <i>Haematologica</i> , <b>2018</b> , 103, 1065-1072	6.6	6
15	Impact of Neurodegenerative Diseases on Drug Binding to Brain Tissues: From Animal Models to Human Samples. <i>Neurotherapeutics</i> , <b>2018</b> , 15, 742-750	6.4	5

14	Design and Synthesis of Novel Epigenetic Inhibitors Targeting Histone Deacetylases, DNA Methyltransferase 1, and Lysine Methyltransferase G9a with Efficacy in Multiple Myeloma. <i>Journal of Medicinal Chemistry</i> , <b>2021</b> , 64, 3392-3426	8.3	5
13	Novel pharmacological maps of protein lysine methyltransferases: key for target deorphanization. <i>Journal of Cheminformatics</i> , <b>2018</b> , 10, 32	8.6	4
12	Conformational Selection versus Induced Fit in Kinases: The Case of PI3K- $\beta$ <i>Angewandte Chemie</i> , <b>2012</b> , 124, 666-670	3.6	3
11	Centralizing discovery information: from logistics to knowledge at a public organization. <i>Combinatorial Chemistry and High Throughput Screening</i> , <b>2011</b> , 14, 429-49	1.3	3
10	Dual Targeting of G9a and DNA Methyltransferase-1 for the Treatment of Experimental Cholangiocarcinoma. <i>Hepatology</i> , <b>2021</b> , 73, 2380-2396	11.2	3
9	Phenotypic Screening To Discover Novel Chemical Series as Efficient Antihemorrhagic Agents. <i>ACS Medicinal Chemistry Letters</i> , <b>2018</b> , 9, 428-433	4.3	2
8	Dual epigenetic modifiers for cancer therapy. <i>Molecular and Cellular Oncology</i> , <b>2017</b> , 4, e1342748	1.2	2
7	Ompalisib inspired macrocycles as dual PI3K/mTOR inhibitors. <i>European Journal of Medicinal Chemistry</i> , <b>2021</b> , 211, 113109	6.8	2
6	Dual Pharmacological Targeting of HDACs and PDE5 Inhibits Liver Disease Progression in a Mouse Model of Biliary Inflammation and Fibrosis. <i>Cancers</i> , <b>2020</b> , 12,	6.6	1
5	Inhibition of the Methyltransferase G9a with Small Molecules As a New Therapeutic Strategy for Treatment of Hematological Malignancies. <i>Blood</i> , <b>2014</b> , 124, 3532-3532	2.2	1
4	Targeting aberrant DNA methylation in mesenchymal stromal cells as a treatment for myeloma bone disease		1
3	P230Metalloproteinases inhibition: a new approach to reduce hemorrhage and blood transfusions. <i>Cardiovascular Research</i> , <b>2014</b> , 103, S41.2-S41	9.9	
2	Novel Soluble Epoxide Hydrolase Inhibitors Featuring a 2-Oxaadamantane Moiety: Synthesis, in vitro Profiling and in vivo Evaluation in Murine Models of Acute Pancreatitis. <i>FASEB Journal</i> , <b>2018</b> , 32, 560.6	0.9	
1	Therapeutics discovery: From bench to first in-human trials. <i>Biomedical Reports</i> , <b>2018</b> , 8, 275-282	1.8	